神经丝轻链蛋白作为帕金森病神经退行性变与生存的生物标志物
研究基于Umeå新发帕金森病队列(n=99)并另用新发队列(n=194)独立验证,探讨诊断前后脑脊液神经丝轻链蛋白(cNfL)与病情严重程度及生存的关系。结果显示早期cNfL越高,除震颤外各项核心运动症状越重、嗅觉受损、生存期越短,并与纹状体多巴胺转运体摄取不足及扩散张量成像各轴索束各向异性分数降低相关。
要点
- 早期cNfL升高与除震颤外的核心运动症状更重相关
- cNfL高于中位数903 ng/L者随访期死亡风险增加5.8倍
- cNfL可反映神经退行性变强度,有望用于未来临床试验
核心结论
- cNfL可作为帕金森病疾病严重程度的生物标志物并预测生存。
- 结果提示cNfL浓度反映神经退行性变过程的强度,对未来临床试验可能重要。
研究设计与样本
- 基于人群的Umeå新发帕金森综合征(NYPUM)研究队列,新发帕金森病患者n=99。
- 另用较大的新发帕金森病队列(n=194)进行独立验证。
- 结合纹状体多巴胺转运体显像及基线、1年和3年重复扩散张量成像分析脑病理与cNfL浓度的关联。
主要发现
- 两个队列中,帕金森病早期cNfL较高与除震颤外所有核心运动症状更严重相关。
- 早期cNfL较高与生存期更短和嗅觉受损相关。
- cNfL高于中位数903 ng/L者随访期间总体死亡风险增加5.8倍。
- 校正年龄和性别后,cNfL较高与纹状体多巴胺转运体摄取缺陷及多个轴索束扩散张量成像各向异性分数降低相关。
关键数值与推荐
- cNfL中位数为903 ng/L,高于该值者随访期总体死亡风险增加5.8倍。
- 证据等级:本研究提供Class II证据,表明帕金森病患者cNfL浓度与更严重疾病和更短生存相关。
临床怎么用
- 对新发帕金森病患者可考虑检测脑脊液cNfL以辅助评估疾病严重程度和预后。
- cNfL升高提示神经退行性变过程较强,可用于临床试验中的分层或疗效评估探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether neurofilament light chain protein in CSF (cNfL), a sensitive biomarker of neuroaxonal damage, reflects disease severity or can predict survival in Parkinson disease (PD). METHODS: We investigated whether disease severity, phenotype, or survival in patients with new-onset PD correlates with cNfL concentrations around the time of diagnosis in the population-based New Parkinsonism in Umeå (NYPUM) study cohort (n = 99). A second, larger new-onset PD cohort (n = 194) was used for independent validation. Association of brain pathology with the cNfL concentration was examined with striatal dopamine transporter imaging and repeated diffusion tensor imaging at baseline and 1 and 3 years. RESULTS: Higher cNfL in the early phase of PD was associated with greater severity of all cardinal motor symptoms except tremor in both cohorts and with shorter survival and impaired olfaction. cNfL concentrations above the median of 903 ng/L conferred an overall 5.8 times increased hazard of death during follow-up. After adjustment for age and sex, higher cNfL correlated with striatal dopamine transporter uptake deficits and lower fractional anisotropy in diffusion tensor imaging of several axonal tracts. CONCLUSIONS: cNfL shows usefulness as a biomarker of disease severity and to predict survival in PD. The present results indicate that the cNfL concentration reflects the intensity of the neurodegenerative process, which could be important in future clinical trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with PD, cNfL concentrations are associated with more severe disease and shorter survival.
引用
- Bäckström D, Linder J, Jakobson Mo S, et al. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology. 2020. PMID: 32680941. doi:10.1212/WNL.0000000000010084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。